Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006480 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006480 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center.
The verdict
NCT00006480, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy and gene therapy in treating children who have recurrent or refractory neuroblastoma.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- DRUG chemotherapy
- DRUG ganciclovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-05 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006480
The ClinicalTrials.gov registry entry for NCT00006480 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which therapeutic autologous lymphocytes is the first listed.
NCT00006480 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006480 about?
NCT00006480 is a clinical study titled "Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effe...
What is the current status of trial NCT00006480?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-05. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00006480?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), chemotherapy (DRUG), ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00006480?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.